Objective
The objective of the study is to compare Gilead’s Voluntary Licensing approach to alternatives including compulsory licensing, voluntary licensing through the Medicines Patent Pool, and no licensing.
Study sites
The study will select 3 country sites based on the speed and volume of program uptake.
Key informants will include relevant representatives from the Medicines Patent Pool, Gilead, multilateral agencies, and national health agencies in country sites.
Methods
The study will use qualitative interviewing with key informants selected to provide unique perspectives on the development of the Gilead Access Program.
The quantitative analysis will examine publicly available procurement data of medicines included in the Gilead voluntary licensing programs.
Evaluation of Gilead Access Program 